NASDAQ:ATRA Atara Biotherapeutics (ATRA) Stock Price, News & Analysis $12.24 +0.75 (+6.53%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Atara Biotherapeutics Stock (NASDAQ:ATRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atara Biotherapeutics alerts:Sign Up Key Stats Today's Range$11.62▼$12.3650-Day Range$7.72▼$13.0252-Week Range$5.01▼$18.70Volume65,302 shsAverage Volume111,445 shsMarket Capitalization$85.92 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingModerate Buy Company Overview Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Read More Atara Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreATRA MarketRank™: Atara Biotherapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 84th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAtara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAtara Biotherapeutics has received no research coverage in the past 90 days.Read more about Atara Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($10.39) to ($10.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -28.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -28.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.51% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 21.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.87 Percentage of Shares Shorted5.51% of the float of Atara Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverAtara Biotherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atara Biotherapeutics has recently decreased by 21.42%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment1.49 News SentimentAtara Biotherapeutics has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Atara Biotherapeutics this week, compared to 2 articles on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $856,839.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Atara Biotherapeutics is held by insiders.Percentage Held by Institutions70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atara Biotherapeutics' insider trading history. Receive ATRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Stock News HeadlinesInsider Buying: Atara Biotherapeutics (NASDAQ:ATRA) Major Shareholder Purchases 55,000 Shares of StockAugust 20 at 5:41 AM | insidertrades.comInnovation Ltd Panacea Purchases 19,335 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) StockJuly 22, 2025 | insidertrades.comTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.August 22 at 2:00 AM | Porter & Company (Ad)Equities Analysts Issue Forecasts for ATRA Q1 EarningsAugust 22 at 2:17 AM | americanbankingnews.comAtara Biotherapeutics: Q2 Earnings SnapshotAugust 11, 2025 | sfgate.comAtara Biotherapeutics Announces Second Quarter Financial Results and Operational ProgressAugust 11, 2025 | uk.finance.yahoo.comAtara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The CornerAugust 5, 2025 | finance.yahoo.comAtara Biotherapeutics stock jumps after FDA accepts BLA for tab-celJuly 24, 2025 | investing.comSee More Headlines ATRA Stock Analysis - Frequently Asked Questions How have ATRA shares performed this year? Atara Biotherapeutics' stock was trading at $13.31 at the beginning of 2025. Since then, ATRA shares have decreased by 9.6% and is now trading at $12.0290. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its quarterly earnings data on Monday, August, 11th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.51. The biotechnology company earned $17.58 million during the quarter, compared to analyst estimates of $4.23 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 8.34% and a net margin of 3.07%. When did Atara Biotherapeutics' stock split? Atara Biotherapeutics shares reverse split before market open on Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Atara Biotherapeutics' major shareholders? Top institutional shareholders of Atara Biotherapeutics include Geode Capital Management LLC (1.01%), Marshall Wace LLP (0.71%), Bank of America Corp DE (0.11%) and Raymond James Financial Inc. (0.06%). Insiders that own company stock include Innovation Ltd Panacea, Anhco Nguyen, Pascal Touchon, Eric J Hyllengren, Yanina Grant-Huerta, Jill Henrich, Carol Giltner Gallagher, Jakob Dupont, Amar Murugan, William K Heiden and Utpal Koppikar. View institutional ownership trends. How do I buy shares of Atara Biotherapeutics? Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and FuelCell Energy (FCEL). Company Calendar Last Earnings8/11/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATRA CIK1604464 Webwww.atarabio.com Phone(805) 623-4211FaxN/AEmployees330Year Founded2012Price Target and Rating Average Price Target for Atara Biotherapeutics$21.00 High Price Target$25.00 Low Price Target$17.00 Potential Upside/Downside+82.8%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$85.40 million Net Margins3.07% Pretax Margin3.05% Return on Equity-8.34% Return on Assets6.61% Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.70 Sales & Book Value Annual Sales$128.94 million Price / Sales0.63 Cash FlowN/A Price / Cash FlowN/A Book Value($4.99) per share Price / Book-2.30Miscellaneous Outstanding Shares7,020,000Free Float6,742,000Market Cap$80.66 million OptionableOptionable Beta0.26 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ATRA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.